SCHEMBL131383

SCHEMBL131383

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@]45C[C@@H]4CC[C@]5(C)[C@H]3CC[C@]12C

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1L1 Q9UHC9 10/20 0.70
▸ USP2 O75604 3/20 0.70
▸ LMNA P02545 3/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ TP53 P04637 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ INPP5D Q92835 1/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ CDC25A P30304 3/20 0.51
▸ CDC25B P30305 1/20 0.51
▸ POLA1 P09884 1/20 0.49
▸ OSBP P22059 2/20 0.49
▸ OSBP2 Q969R2 2/20 0.49
▸ ABCB1 P08183 1/20 0.49
▸ RORC P51449 1/20 0.49
▸ CYP46A1 Q9Y6A2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14007452 1.00 NPC1L1 (0.70) NPC1L1USP2LMNAMEN1TP53
SCHEMBL15107562 1.00 NPC1L1 (0.70) NPC1L1USP2LMNAMEN1TP53
SCHEMBL13988168 1.00 NPC1L1 (0.70) NPC1L1USP2LMNAMEN1TP53
SCHEMBL1937432 0.88 CYP2D6 (0.60) NPC1L1USP2LMNAMEN1TP53
SCHEMBL24632922 0.86 NPC1L1 (0.57) NPC1L1USP2LMNAMEN1TP53
SCHEMBL30088637 0.86 NPC1L1 (0.57) NPC1L1USP2LMNAMEN1TP53
SCHEMBL22872157 0.86 NPC1L1 (0.57) NPC1L1USP2LMNAMEN1TP53
SCHEMBL3466236 0.86 NPC1L1 (0.57) NPC1L1USP2LMNAMEN1TP53
SCHEMBL11823008 0.86 NPC1L1 (0.52) NPC1L1USP2LMNAMEN1TP53
SCHEMBL21883650 0.84 NPC1L1 (0.81) NPC1L1USP2LMNAMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772003-B2 Lipid derivatives of aminoglycosides AVENTIS PHARMA S.A. (FR) 2010-08-10 — — US claimed
US-7641914-B2 for forming conjugates (liposomes, complexes, nanoparticles) with biologically active substances and releasing them into cellular tissues or acidic compartments, or for use as nonionic surfactant for stabilizing particles encapsulating biodrugs GENCELL, S.A. (FR) 2010-01-05 — — US claimed
EP-1430074-B1 AMINOGLYCOSIDE LIPID DERIVATIVES FOR TRANSFECTION AVENTIS PHARMA SA (FR) 2009-05-06 — — EP claimed
EP-0984925-B1 COMPOUNDS, PREPARATION AND USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS AVENTIS PHARMA SA (FR) 2004-12-08 — — EP claimed
US-6812218-B2 TRANSFERRING NUCLEIC ACIDS TO CELLS GENCELL S.A. (FR) 2004-11-02 — — US claimed
US-20030065033-A1 Lipid derivatives of polythiourea GENCELL S.A. (FR) 2003-04-03 — — US claimed
EP-0986568-B1 NOVEL CLASS OF NUCLEIC ACID CATIONIC TRANSFECTING AGENTS AVENTIS PHARMA SA (FR) 2002-03-20 — — EP claimed
US-6300321-B1 LIPOPOLYAMINES AVENTIS PHARMA S.A. (FR) 2001-10-09 — — US claimed
US-8790664-B2 Multimodular assembly useful for intracellular delivery INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2014-07-29 — — US disclosed
US-20120058139-A1 NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2012-03-08 — — US disclosed
EP-2331071-A1 NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY Institut National De La Sante Et De La Recherche Medicale (FR) 2011-06-15 — — EP disclosed
US-7772003-B2 Lipid derivatives of aminoglycosides AVENTIS PHARMA S.A. (FR) 2010-08-10 — — US disclosed
WO-2010026537-A1 NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2010-03-11 — — WO disclosed
US-7641914-B2 for forming conjugates (liposomes, complexes, nanoparticles) with biologically active substances and releasing them into cellular tissues or acidic compartments, or for use as nonionic surfactant for stabilizing particles encapsulating biodrugs GENCELL, S.A. (FR) 2010-01-05 — — US disclosed
US-6300321-B1 LIPOPOLYAMINES AVENTIS PHARMA S.A. (FR) 2001-10-09 — — US disclosed
EP-1068188-A1 NOVEL NUCLEIC ACID TRANSFER AGENTS, COMPOSITIONS CONTAINING SAME AND USES Aventis Pharma S.A. (FR) 2001-01-17 — — EP disclosed
EP-0986568-A1 NOVEL CLASS OF NUCLEIC ACID CATIONIC TRANSFECTING AGENTS Aventis Pharma S.A. (FR) 2000-03-22 — — EP disclosed
WO-1999051581-A1 NOVEL NUCLEIC ACID TRANSFER AGENTS, COMPOSITIONS CONTAINING SAME AND USES AVENTIS PHARMA S.A. (FR) 1999-10-14 — — WO disclosed
WO-1998055490-A1 NOVEL CLASS OF NUCLEIC ACID CATIONIC TRANSFECTING AGENTS RHONE-POULENC RORER S.A. (FR) 1998-12-10 — — WO disclosed
US-3994878-A Syntheses of 24R,25- and 24S,25-dihydroxycholesterol and alkanoyl derivatives thereof HOFFMANN-LA ROCHE INC. (US) 1976-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058139-A1 NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY PICALM, CHMP4B, CLTB NPC1L1 30/4885USP2 2902/4885LMNA 1451/4885
US-20030065033-A1 Lipid derivatives of polythiourea ABCB4, TENT4A, PEBP1 NPC1L1 64/4885USP2 3014/4885LMNA 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback